Alzheimer's Drug Discovery Foundation (ADDF)

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Drug Discovery Foundation (ADDF)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Non-profit venture philanthropy</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>New York, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>501(c)(3) Non-Profit Organization</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.alzdiscovery.org/" target="_blank">https://www.alzdiscovery.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease) Drug Discovery, Diagnostics, Biomarkers</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1998</td>
</tr>
<tr>
<td class="label">Co-Founders</td>
<td>Leonard A. Lauder, Howard Fillit, MD</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Isobel Coleman</td>
</tr>
<tr>
<td class="label">Diagnostics Accelerator</td>
<td>$150 million initiative</td>
</tr>
</table>

Alzheimer's Drug Discovery Foundation (ADDF)

Overview

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Drug Discovery Foundation (ADDF)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Non-profit venture philanthropy</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>New York, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>501(c)(3) Non-Profit Organization</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.alzdiscovery.org/" target="_blank">https://www.alzdiscovery.org/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease) Drug Discovery, Diagnostics, Biomarkers</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1998</td>
</tr>
<tr>
<td class="label">Co-Founders</td>
<td>Leonard A. Lauder, Howard Fillit, MD</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Isobel Coleman</td>
</tr>
<tr>
<td class="label">Diagnostics Accelerator</td>
<td>$150 million initiative</td>
</tr>
</table>

Alzheimer's Drug Discovery Foundation (ADDF)

Overview

The Alzheimer's Drug Discovery Foundation (ADDF) is a leading non-profit organization dedicated to accelerating the development of therapeutics for Alzheimer's disease and related dementias. Founded in 1998 by Leonard A. Lauder and Howard Fillit, MD, the ADDF employs a unique venture philanthropy model, making strategic investments in promising research programs and using returns to fund additional research[@about].

Based in New York City, the ADDF has grown to become the leading non-profit funder of Alzheimer's drug discovery, having invested hundreds of millions of dollars in research worldwide. Unlike traditional charitable foundations that provide grants, the ADDF makes equity investments in biotechnology companies, providing both funding and strategic guidance to advance promising therapeutic approaches.

The organization's mission is to rapidly accelerate the development of effective drugs to prevent, treat, and cure Alzheimer's disease and related dementias. To achieve this mission, the ADDF focuses on supporting novel therapeutic approaches that target the biological mechanisms of aging rather than traditional amyloid-focused strategies.

History and Foundation

Founding and Early Years

The ADDF was founded in 1998 by Leonard A. Lauder, former chairman and CEO of Estée Lauder Companies, and Howard Fillit, MD, a physician-scientist specializing in geriatric medicine. The founding was motivated by the recognition that traditional research funding mechanisms were insufficient to drive the development of effective Alzheimer's therapies.

Leonard Lauder's involvement was deeply personal — his mother had died from Alzheimer's disease, and he was committed to finding a cure. Howard Fillit brought scientific expertise and a vision for applying venture capital principles to charitable research funding. Together, they created a new model for advancing Alzheimer's drug development.

Growth and Evolution

Since its founding, the ADDF has evolved significantly:

• 1998: Founded as the Alzheimer's Drug Discovery Foundation
• 2000s: Built portfolio of early-stage investments in biotech companies
• 2010: Launched the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) with NIH
• 2015: Expanded focus to include diagnostics and biomarkers
• 2018: Launched the Diagnostics Accelerator program
• 2020: Supported development of numerous COVID-19 programs
• 2023: Launched $150 million phase of Diagnostics Accelerator[@business2023]
• 2024: Continued expansion of funding programs and portfolio

Venture Philanthropy Model

How It Works

The ADDF's venture philanthropy model distinguishes it from traditional charitable foundations[@about]. Key elements include:

Investment Criteria

The ADDF evaluates potential investments based on:

• Scientific Merit: Novel mechanism of action with strong preclinical data
• Team: Experienced management and scientific advisors
• Timeline: Realistic path to clinical development
• Market Opportunity: Significant unmet medical need
• Strategic Fit: Alignment with ADDF research priorities

Funding Programs

Drug Development Program

The core funding mechanism for therapeutic development[@programs]:

Award Structure

• Seed Awards: Up to $150,000 for early-stage research
• Development Awards: Up to $600,000 for preclinical development
• Translation Awards: Up to $1 million for IND-enabling studies

Focus Areas

Excluded Areas

• Amyloid-targeted approaches (monoclonal antibodies, aggregation inhibitors)
• Cholinesterase inhibitors
• Symptomatic treatments
• Generic drug repurposing without novel mechanism

Diagnostics Accelerator

The Diagnostics Accelerator is a $150 million initiative launched in 2018 and significantly expanded in 2023 to advance novel biomarkers for early detection of Alzheimer's disease[@diagnostics][@business2023]:

Focus Areas

• Development of blood tests for Alzheimer's detection
• Validation of biomarker panels
• Point-of-care testing development
• Integration with clinical practice

• Voice and speech analysis
• Movement and gait analysis
• Smartphone-based cognitive assessments
• Wearable device data

• CSF biomarkers
• Imaging agents
• Multi-omics approaches
• Computational diagnostics

• Pre-symptomatic detection
• Risk stratification
• Disease progression markers
• Treatment response biomarkers

Key Initiatives

• Blood Test Initiative: Funding development of blood-based tests that can detect Alzheimer's pathology before symptoms appear
• Digital Biomarker Program: Supporting development of technology-based tools for early detection
• Validation Studies: Funding large-scale validation of promising biomarkers
• Clinical Implementation: Working to move biomarkers from research to clinical use

ADDF-Harrington Scholar Program

A joint program with the Harrington Discovery Institute providing funding and mentorship to accelerate breakthrough discoveries[@harrington]:

Program Features

• Funding: Up to $400,000 over two years
• Mentorship: Access to drug development experts
• Strategic Guidance: Business development support
• Network Access: Connections to pharmaceutical partners

Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD)

A public-private partnership focused on identifying new therapeutic targets and biomarkers[@about]:

Partners

• National Institute on Aging (NIA)
• Pharmaceutical companies
• Academic research institutions

Goals

• Identify novel drug targets
• Develop biomarkers for patient selection
• Share data and resources
• Accelerate clinical trials

Melvin R. Goodes Prize

An award for excellence in Alzheimer's drug development[@goodes]:

Award Details

• $500,000 prize recognizing significant advances
• Annual award to leading researchers
• Named in honor of ADDF board member

2026 Recipient

Frontotemporal Dementia Program

The ADDF has expanded to include frontotemporal dementia (FTD) as a focus area[@ftda]:

Program Features

• Specific funding for FTD research
• Focus on novel therapeutic approaches
• Collaboration with FTD advocacy organizations
• Research on disease mechanisms unique to FTD

SpeechDx Program

A research initiative focused on speech-based diagnostics[@speechdx]:

Focus Areas

• Development of speech analysis tools
• Voice biomarkers for early detection
• Integration with digital health platforms
• Clinical validation studies

Priority Research Areas

The ADDF prioritizes research targeting the fundamental biology of aging that contributes to Alzheimer's disease[@research]:

Neuroinflammation

Neuroinflammation has emerged as a critical driver of Alzheimer's pathogenesis. The ADDF funds research on:

• Microglial Activation: Understanding how immune cells in the brain contribute to neurodegeneration
• Inflammasome Inhibition: Targeting NLRP3 and other inflammasomes
• Cytokine Modulation: Developing anti-inflammatory therapies
• TREM2 Pathways: Supporting research on TREM2 variants and microglial function

Epigenetics

The ADDF recognizes that epigenetic changes during aging contribute to cognitive decline:

• DNA Methylation: Understanding age-related methylation changes
• Histone Modifications: Targeting histone acetylation and deacetylation
• Non-coding RNAs: Exploring microRNA and long non-coding RNA involvement
• Reversibility: Developing drugs that can reverse harmful epigenetic changes

Mitochondrial Dysfunction

Mitochondrial dysfunction is a hallmark of aging and neurodegeneration:

• Bioenergetics: Supporting mitochondrial function
• Oxidative Stress: Protecting against reactive oxygen species
• Mitophagy: Enhancing clearance of damaged mitochondria
• Metabolic Pathways: Addressing brain energy metabolism

Synaptic Health

Synaptic loss correlates strongly with cognitive decline:

• Synaptic Plasticity: Supporting formation and maintenance of synapses
• Presynaptic Function: Understanding neurotransmitter release
• Postsynaptic Density: Targeting scaffold proteins and receptors
• Network Function: Maintaining neural circuit integrity

Vascular Health

Cerebrovascular dysfunction contributes to Alzheimer's pathology:

• Blood-Brain Barrier: Protecting and repairing the BBB
• Cerebral Blood Flow: Maintaining adequate perfusion
• Pericyte Function: Supporting vascular stability
• Angiogenesis: Promoting healthy blood vessel formation

Portfolio Companies

The ADDF has invested in numerous biotechnology companies developing Alzheimer's therapeutics. The portfolio spans multiple therapeutic modalities and mechanisms[@portfolio]:

Anti-Amyloid Approaches (Selected)

While the ADDF does not fund new amyloid-focused programs, its portfolio includes legacy investments:

• Acumen Pharmaceuticals — Anti-amyloid beta oligomer antibodies
• Alzheon — Amyloid aggregation inhibitors
• AC Immune — Anti-amyloid vaccines and antibodies
• Prothena — Amyloid-targeting antibodies

Neuroprotection and Novel Mechanisms

• Axsome Therapeutics — Novel CNS therapeutics
• Cortexyme — Novel anti-infective approach targeting gingipains
• Anavex Life Sciences — Sigma-1 receptor agonists
• Athira Pharma — Neuroprotection via HGF/MET pathway

Tau and Neurofibrillary Pathology

• Alnylam — RNAi therapeutics for tau
• Cerevel Therapeutics — Tau-targeted small molecules
• Pinteon Therapeutics — Tau-targeted immunotherapies

Neuroinflammation

• Denali Therapeutics — LRRK2 inhibitors for neuroinflammation
• NodThera — NLRP3 inflammasome inhibitors
• Inmune Bio — Cytokine modulation

Other Notable Investments

• Alector — Immune-glial targeting
• Lexeo Therapeutics — Gene therapy for Alzheimer's
• Life Biosciences — Multi-target approach
• Neumora Therapeutics — Precision neurology

Leadership

Executive Team

• Isobel Coleman — Chief Executive Officer
• Howard Fillit, MD — Co-Founder and Chief Science Officer
• Leonard A. Lauder — Co-Founder and Co-Chairman (emeritus)

Board of Directors

The ADDF is governed by a distinguished board including:

• Business leaders from pharmaceutical and finance industries
• Scientific advisors with expertise in neurodegeneration
• Patient advocates

Scientific Advisory Board

The organization benefits from leading scientists in:

• Alzheimer's research
• Drug development
• Biomarker development
• Clinical trials

Impact and Accomplishments

Research Impact

The ADDF's investments have contributed to:

Portfolio Success

The ADDF portfolio includes:

• Companies that have gone public
• Therapies in late-stage clinical trials
• Strategic acquisitions by pharmaceutical companies
• FDA approvals for portfolio companies

Field Leadership

The ADDF has become a thought leader in:

• Alternative therapeutic approaches
• Diagnostics development
• Venture philanthropy in neurodegeneration
• Open science and data sharing

Financial Overview

The ADDF operates as a 501(c)(3) non-profit organization with a unique financial model[@about]:

Revenue Sources

• Donations and contributions
• Investment returns
• Foundation grants

Investment Returns

• Returns are reinvested in research
• Supports sustainable funding model

Financial Scale

• Total funding: Hundreds of millions invested
• Diagnostics Accelerator: $150 million commitment
• Annual grant-making: Significant annual expenditures

Collaboration and Partnerships

Academic Partnerships

The ADDF collaborates with leading research institutions:

• University research centers
• Medical schools
• Teaching hospitals
• Research institutes

Pharmaceutical Partnerships

Working with major pharmaceutical companies:

• Drug development collaborations: Co-development agreements with pharmaceutical partners
• Clinical trial partnerships: Support for industry-sponsored trials
• Data sharing initiatives: Open science collaborations
• Target validation programs: Joint validation of novel targets
• Patient access programs: Supporting patient access to experimental therapies

Government Partnerships

The ADDF works closely with government research agencies:

• National Institute on Aging (NIH): Largest single funder of Alzheimer's research, collaborating on AMP-AD and other initiatives
• European Union research programs: Participation in EU-funded dementia research
• National dementia strategies: Advisory role in national Alzheimer's plans
• FDA engagement: Dialogue with regulatory agencies on biomarker development and clinical trial design

Non-Profit Partnerships

The ADDF collaborates with other non-profit organizations:

• Alzheimer's Association: Joint initiatives on research and advocacy
• Alzheimer's Disease International: Global collaboration on awareness and research
• Patient advocacy organizations: Partnerships with disease-specific organizations
• Research foundations: Collaboration with other disease-focused foundations
• Family foundations: Partnerships with other family philanthropies

Detailed Program Descriptions

Drug Development Program Deep Dive

The Drug Development Program is the cornerstone of ADDF funding[@programs]:

Stage-Specific Funding

Discovery Stage (Seed Awards)

• Maximum award: $150,000
• Duration: 12-18 months
• Focus: Target validation, lead identification
• Eligible activities: In vitro studies, preliminary animal work, medicinal chemistry

• Maximum award: $600,000
• Duration: 18-24 months
• Focus: Lead optimization, IND-enabling studies
• Eligible activities: Pharmacokinetics, toxicology, formulation development

• Maximum award: $1,000,000
• Duration: 24-36 months
• Focus: IND-enabling to Phase I
• Eligible activities: GMP manufacturing, regulatory support, Phase I trials

Review Process

Applications undergo rigorous peer review:

Diagnostics Accelerator Deep Dive

The Diagnostics Accelerator represents a transformative investment in Alzheimer's diagnostics[@diagnostics]:

Funding Initiatives

Blood-Based Biomarker Program
The ADDF has prioritized blood-based biomarkers as the most promising approach to early detection. Current projects include:

• Plasma Aβ42/40 ratio assays
• p-tau217 and p-tau181 measurements
• Neurofilament light chain (NfL) testing
• Multi-marker panels for improved accuracy

• Voice analysis for cognitive assessment
• Smartphone-based cognitive testing
• Wearable device data for movement analysis
• Passive monitoring systems

• Novel CSF marker validation
• Less invasive collection methods
• Point-of-care CSF testing

Strategic Partnerships

The Diagnostics Accelerator works with:

• Leading diagnostic companies
• Academic medical centers
• Pharmaceutical companies
• Regulatory agencies

ADDF-Harrington Scholar Program Details

The ADDF-Harrington Scholar Program combines ADDF's scientific expertise with Harrington's drug development capabilities[@harrington]:

Scholar Benefits

• Funding: Up to $400,000 over two years
• Mentorship: Access to team of drug development experts
• Business Development: Support for commercialization
• Network Access: Connections to pharmaceutical partners

Selection Criteria

• Scientific innovation
• Translational potential
• Team capabilities
• Institutional support

AMP-AD Partnership Details

The Accelerating Medicines Partnership for Alzheimer's Disease represents a unique public-private collaboration[@about]:

Consortium Structure

• Academic Partners: Multiple universities and research centers
• Government Partners: NIH/NIA
• Pharmaceutical Partners: Major pharmaceutical companies

Data Sharing

The partnership has created an unprecedented data resource:

• Genomics data from thousands of brains
• Transcriptomics across disease progression
• Proteomics and metabolomics data
• Clinical data integration

Frontotemporal Dementia Program

The ADDF's FTD program addresses a significant unmet need[@ftda]:

Program Focus

• Genetic Forms: Support for research on GRN, MAPT, C9orf72 mutations
• Sporadic FTD: Understanding non-genetic forms
• Clinical Trials: Supporting intervention studies
• Biomarkers: Developing FTD-specific biomarkers

Collaboration

The FTD program works with:

• FTD advocacy organizations
• Academic FTD centers
• Pharmaceutical companies with FTD programs

Impact Assessment

Scientific Impact

The ADDF's investments have contributed to significant scientific advances:

Industry Impact

The ADDF has influenced the pharmaceutical industry:

Field Leadership

The ADDF has become a thought leader:

Financial Model Details

Revenue and Investment

The ADDF operates on a unique financial model[@about]:

Revenue Sources

• Individual Donors: Major gifts from individuals
• Foundation Grants: Support from other foundations
• Corporate Partners: Pharmaceutical and diagnostic companies
• Investment Returns: Returns from portfolio companies

Investment Returns

• Equity Appreciation: Value increases in portfolio companies
• Exit Events: IPOs and acquisitions generate returns
• Dividend Income: Some investments generate income
• Reinvestment: Returns are recycled into new investments

Financial Scale

• Total Capital Invested: Hundreds of millions across portfolio
• Annual Grant-making: Significant annual expenditure on new awards
• Diagnostics Accelerator: $150 million committed over multiple years
• Administrative Efficiency: Low overhead maximizes research funding

Governance and Operations

Governance Structure

The ADDF is governed by:

• Board of Directors: Strategic oversight and fiduciary responsibility
• Scientific Advisory Board: Scientific direction and review
• Investment Committee: Investment decisions and portfolio management

Operational Efficiency

The ADDF maintains:

• Lean Operations: Small team maximizes research funding
• Expertise: Staff with drug development and scientific expertise
• Network: Extensive network of collaborators and advisors
• Flexibility: Ability to move quickly on promising opportunities

Future Directions

The ADDF continues to evolve and expand its impact[@about][@news2024]:

Strategic Priorities

• Understanding heterogeneity in Alzheimer's pathogenesis
• Targeting specific molecular subtypes
• Personalized treatment approaches

• Combining novel mechanisms with traditional approaches
• Multi-target interventions
• Rational drug combinations

• Identifying at-risk individuals
• Early intervention strategies
• Lifestyle modification studies

• Surrogate endpoints for faster trials
• Patient stratification
• Treatment response monitoring

Growth Areas

The ADDF is expanding into new areas:

• Expanded FTD Program: Increased focus on frontotemporal dementia
• Additional Diagnostic Modalities: Beyond blood and digital biomarkers
• International Partnerships: Expanded global collaboration
• New Funding Mechanisms: Alternative structures for larger programs

Emerging Priorities

• Glial Biology: Understanding microglia and astrocytes in disease
• Metabolism: Brain metabolism and metabolic dysfunction
• Circadian Rhythms: Sleep and circadian contributions to neurodegeneration
• Multi-Omics: Integration of genomics, proteomics, and metabolomics

Related Organizations and Topics

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-trials)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Primary Progressive Aphasia](/diseases/primary-progressive-aphasia)

Related Therapeutic Approaches

• [Anti-Amyloid Therapies](/therapeutics/anti-amyloid-therapeutics)
• [Anti-Tau Therapies](/therapeutics/anti-tau-therapeutics)
• [Neuroprotection](/therapeutics/neuroprotection)
• [Anti-Inflammatory Therapies](/therapeutics/anti-inflammatory-therapies)
• [Epigenetic Therapies](/therapeutics/epigenetic-therapies)
• [Mitochondrial Therapies](/therapeutics/mitochondrial-therapies)
• [Vascular Therapies](/therapeutics/vascular-therapies)

Related Institutions

• [NIH National Institute on Aging](/institutions/nih-national-institute-on-aging)
• [Alzheimer's Association](/institutions/alzheimers-association)
• [Alzheimer's Clinical Trial Consortium](/institutions/alzheimers-clinical-trial-consortium)
• [Banner Alzheimer's Institute](/institutions/banner-alzheimers-institute)

Contact Information

• Address: 57 West 57th Street, Suite 904, New York, NY 10019
• Email: info@alzdiscovery.org
• Phone: 212.901.8000
• Website: www.alzdiscovery.org
• Tax Status: 501(c)(3) non-profit organization

References

See Also

Related Hypotheses:

• [Glycine-Rich Domain Competitive Inhibition](/hypotheses/h-7e846ceb)
• [Purinergic Signaling Polarization Control](/hypotheses/h-0758b337)
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypotheses/h-044ee057)
• [APOE-TREM2 Interaction Modulation](/hypotheses/h-180807e5)
• [TREM2-Mediated Selective Aggregate Clearance Pathway](/hypotheses/h-3460f820)

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402)
• [sda-2026-04-01-001](/analysis/sda-2026-04-01-001)
• [sda-2026-04-01-003](/analysis/sda-2026-04-01-003)

• [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)